Search Details

Word: poulenc (lookup in dictionary) (lookup stats)
Dates: during 1990-1999
Sort By: most recent first (reverse)


Usage:

...whose subsidiary Searle makes the wildly successful arthritis drug Celebrex, has been casting around for a merger partner for over a year, and now, executives say, the search is over. Monsanto will merge with Pharmacia & Upjohn, joining the ranks of other mega-merger firms like Astra-Zeneca and Rhone-Poulenc-Hoechst, to form a corporation worth about $52 billion. Why did it take so long for Monsanto to find its mate, and why was Pharmacia willing to take it on? The answers lie in Monsanto's agri-chemical division, a successful but controversial arm of the company, which...

Author: /time Magazine | Title: The Bride of Frankenfoods | 12/20/1999 | See Source »

...money that the medical center has been aggressively pursuing in recent years. Last fall Duke opened a new 10,000-sq.-ft. laboratory, a set of "clean rooms" where cell cultures can be cultivated in sterile surroundings. The $1.5 million facility was paid for by the pharmaceutical giant Rhone-Poulenc Rorer, based in Collegeville, Pa. But this particular deal is unusual in that the company has no commercial claim on any products developed through the use of the new lab. Sue Strauss is one of 18 Duke patients in Lyerly's trial, one of several vaccine tests approved...

Author: /time Magazine | Title: I Wasn't Going to Curl Up and Die | 10/12/1998 | See Source »

...their own. Whenever antibiotics are used indiscriminately, mildly resistant bacteria survive and breed with one another, creating increasingly resistant germs. Pharmaceutical companies are racing to create new antibiotics that can replace vancomycin as the drug of last recourse. The leading candidate: Synercid, an experimental drug being developed by Rhone-Poulenc Rorer. Tests show that it should defeat even vancomycin-resistant staphylococci--at least until a tougher strain of bacteria evolves...

Author: /time Magazine | Title: GERM WARFARE | 9/1/1997 | See Source »

...Hurwitz, an analyst for Robertson, Stephens & Co. The list of recent mergers, as Hurwitz ticks them off, reads like a Who's Who of biotechnology: "Sandoz buys Genetics Institute. Chiron buys Viagene. Bristol Myers makes a big investment in Somatix. Merck makes a big investment in Vical. Rhone-Poulenc invests in Applied Immune Sciences and several other gene-therapy companies...

Author: /time Magazine | Title: HAS GENE THERAPY STALLED? | 10/9/1995 | See Source »

University Art Museums. Presents pianist David Korevaar performing works by Faure, Stravinsky, Hindemith and Poulenc. Fogg Museum, 5:30 p.m. $4 forstudents...

Author: NO WRITER ATTRIBUTED | Title: at harvard | 4/20/1995 | See Source »

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next